• Ascendis Pharma recently reported Phase 2 COACH trial data showing that combining once-weekly TransCon CNP and TransCon hGH improved growth, arm span, spinal canal dimensions, and lower limb alignment in children with achondroplasia over 52 weeks, with all participants completing a full year of therapy.
• In parallel, the company secured U.S. orphan drug exclusivity for YUVIWEL through February 27, 2033 and began its commercial U.S. launch, potentially strengthening its rare-disease growth franchise and clarifying the regulatory framework around this new once-weekly achondroplasia treatment.
• We’ll now consider how the new COACH combination data, especially the meaningful arm span gains, may influence Ascendis Pharma’s existing investment narrative.

Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Ascendis Pharma Investment Narrative Recap

To own Ascendis Pharma, you need to believe its TransCon platform can turn today’s loss-making rare-disease portfolio into a durable, multi-product business anchored by YORVIPATH, SKYTROFA and now YUVIWEL. In the near term, the key catalyst is how quickly YUVIWEL and existing growth drugs convert into recurring, reimbursed revenue, while the main risk remains high spend and execution across multiple launches. The new COACH data strengthens the achondroplasia story, but does not remove trial, regulatory, or payer risk.

The most relevant recent announcement is YUVIWEL’s U.S. orphan drug exclusivity through February 27, 2033 and the start of its commercial launch. This matters because it backs the achondroplasia franchise with regulatory protection and early revenue, just as combination data from COACH highlight a broader clinical thesis around TransCon CNP. Together, they frame how future label expansions or combo approvals could act as meaningful, though still uncertain, catalysts.

Yet behind the clinical wins, investors should be aware that rising R&D and commercial spend could still...

Ascendis Pharma's narrative projects €2.5 billion revenue and €1.1 billion earnings by 2029.

Uncover how Ascendis Pharma's forecasts yield a $289.37 fair value, a 21% upside to its current price.

Exploring Other Perspectives

Some analysts were far more cautious, assuming revenue of about €1.6 billion and earnings of roughly €303 million by 2028, so this new achondroplasia data could eventually challenge those more pessimistic views.

Explore 4 other fair value estimates on Ascendis Pharma - why the stock might be worth just $248.32!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Ascendis Pharma research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Ascendis Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ascendis Pharma's overall financial health at a glance.

Looking For Alternative Opportunities?

Our top stock finds are flying under the radar-for now. Get in early:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.